ALTERITY THERAPEUTICS LTD

Alterity Therapeutics Limited is a development-stage medical biotechnology company focused on discovering and developing therapeutic drugs for neurodegenerative diseases, specifically Parkinsonian and other movement disorders ¹. The company's core mission, since its incorporation on November 11, 1997 ², has remained centered on this class of diseases. Alterity operates in a highly competitive pharmaceutical industry, facing numerous competitors globally, including major pharmaceutical companies, biotechnology firms, universities, and other research institutions ³. These competitors often possess greater financial, technical, manufacturing, and marketing capabilities, as well as more experience in clinical trials and regulatory approvals ⁴.

The company's core business model is centered on the research and development of novel chemical compounds to address the underlying pathology of neurodegenerative disorders. Revenue generation primarily stems from government grants, licensing and research collaborations, and interest income, as the company has not yet commercialized any products ⁵. The business model is characterized by significant research and development expenditures and a reliance on external funding due to recurring losses since inception ⁶.

Alterity's lead drug candidate is ATH434, a small molecule designed to block the accumulation and aggregation of α-synuclein, a protein implicated in neurodegeneration ⁷. Preclinically, ATH434 has demonstrated the ability to redistribute excess labile iron in the central nervous system, reduce α-synuclein aggregation, preserve neurons and support cells, and stabilize or improve function ⁸. This mechanism suggests potential for treating iron-mediated diseases such as Parkinson's disease and Multiple System Atrophy (MSA) ⁹. ATH434 has been granted Fast Track designation by the US FDA for MSA, which aims to facilitate and expedite development and review for serious conditions with unmet medical needs ¹⁰. It also holds Orphan Drug designation for MSA from both the US FDA and the European Commission, providing seven years of market exclusivity in the United States and ten years in the European Union following approval ¹¹.

In the fiscal year ended June 30, 2025, Alterity reported a net loss of A$12,147,828 ¹², an improvement from a net loss of A$19,123,464 in the prior year ¹³. Interest income increased to A$446,291 ¹⁴ from A$268,419 in 2024 ¹⁵, a 66.3% increase ¹⁶, primarily due to higher Australian dollar cash balances and interest rates ¹⁷. Other income for the year was A$7,641,516 ¹⁸, which included A$5,438,918 from the R&D Tax Incentive ¹⁹, A$1,513,590 from the ATO for settlement of a prior R&D Tax Incentive claim ²⁰, A$1,975,056 from the settlement of a dispute with Catalent ²¹, and A$227,542 from an insurance claim related to a US employment case ²². Research and development expenses decreased by A$4,239,765, or 22.7%, to A$14,404,282 ²³ from A$18,644,047 in 2024 ²⁴, attributed to the finalization of certain R&D studies ²⁵. General and administrative expenses increased by A$718,756, or 15.1%, to A$5,481,399 ²⁶ from A$4,762,643 in 2024 ²⁷, mainly due to increased staffing costs, audit compliance, and consulting expenses ²⁸. Intellectual property expenses decreased by A$86,781, or 40.5%, to A$127,523 ²⁹ from A$214,304 in 2024 ³⁰, reflecting management's cost reduction efforts ³¹. The company recorded a foreign exchange gain of A$259,433 ³² in 2025, compared to a gain of A$261,152 in 2024 ³³. Basic and diluted loss per share improved to (0.19) cents ³⁴ from (0.52) cents in 2024 ³⁵. As of June 30, 2025, cash and cash equivalents stood at A$33,158,642 ³⁶, with A$7,500,000 in longer-dated term deposits ³⁷, compared to A$12,638,885 in cash and cash equivalents in 2024 ³⁸. Total assets were A$46,026,360 ³⁹ and total liabilities were A$3,623,274 ⁴⁰, resulting in net assets of A$42,403,086 ⁴¹. Issued capital was A$262,949,462 ⁴², and accumulated deficit was A$225,888,680 ⁴³. Net operating cash outflow was A$11,451,248 ⁴⁴ for the year ended June 30, 2025, an improvement from A$12,605,824 in 2024 ⁴⁵.

During the fiscal year, Alterity successfully completed two Phase 2 clinical trials for ATH434 in MSA. The ATH434-201 study, a randomized, double-blind, placebo-controlled trial, enrolled 77 adults with MSA ⁴⁶. Topline results announced in January 2025 demonstrated significant slowing of clinical progression and a favorable safety profile, achieving statistical significance on the Modified Unified MSA Rating Scale Part 1 (UMSARS Part 1) ⁴⁷. Additional analyses in May 2025 showed a 48% relative treatment effect at the 50 mg dose (p=0.02) and a 30% relative treatment effect at the 75 mg dose at 52 weeks on UMSARS Part 1 ⁴⁸. The ATH434-202 study, an open-label biomarker trial in up to 15 individuals with advanced MSA ⁴⁹, reported positive interim data in July 2024, showing 43% of participants improved on UMSARS after 6 months ⁵⁰. Topline data in July 2025 indicated ATH434 conferred a clinical benefit and stabilized key biomarkers, with disease progression on UMSARS I reduced by approximately half compared to historical controls ⁵¹. The company also sub-licensed PBT2 and novel zinc modulators for Alzheimer's disease to Professor Colin Masters, M.D., A.O., in March 2023, retaining future royalties on net sales ⁵². In December 2020, Alterity acquired an exclusive worldwide license for novel zinc ionophore technology to combat antimicrobial resistance ⁵³.

Management explicitly states that the company expects to continue incurring losses into the foreseeable future as it expands research and development activities and advances product candidates into later stages of development ⁵⁴. The continuing viability of the Group is contingent on its ability to raise additional capital to finance planned research and development programs, maintain cost containment and deferment strategies, and successfully commercialize its initiatives ⁵⁵. The company successfully raised new equity funding during the 2025 financial year to enable progression of its planned research and development programs for at least the next 12 months ⁵⁶.

A key growth area for Alterity is the continued development of ATH434 for neurodegenerative diseases, particularly Multiple System Atrophy (MSA) and Parkinson's disease. The positive topline results from the ATH434-201 Phase 2 study in MSA, demonstrating significant slowing of clinical progression and a favorable safety profile, are a critical milestone ⁵⁷. The achievement of statistical significance on the Modified Unified MSA Rating Scale Part 1 (UMSARS Part 1) is highlighted as an endpoint needed to support drug approval by the FDA ⁵⁸. The 50 mg dose showed a 48% relative treatment effect (p=0.02) and the 75 mg dose showed a 30% relative treatment effect at 52 weeks on UMSARS Part 1 ⁵⁹. Additionally, the ATH434-202 study in advanced MSA patients showed a reduction in disease progression by approximately half compared to historical controls over 12 months ⁶⁰, with 43% of participants having stable UMSARS scores ⁶¹. These results support the continued advancement of ATH434 for MSA treatment ⁶².

Another growth vector involves the broader application of Alterity's platform technology, which targets the interrelationship of metals and proteins in neurodegeneration. Historically, research has focused on Parkinsonian disorders, Alzheimer's disease, and Huntington disease ⁶³. The company believes this platform may also be applicable for certain cancers, age-related macular degeneration, diabetes mellitus, cardiovascular disease, and other neurodegenerative diseases ⁶⁴. The company continues to develop its 'two-tier' Translational Research program, encompassing new chemical entity design, synthesis, and characterization in the discovery phase, and translational animal modeling programs to test and validate new candidates ⁶⁵. This ongoing research is expected to yield future product candidates across various neurodegenerative and other indications ⁶⁶.

Operationally, the company's research and development expenses decreased to A$14,404,282 ⁶⁷ in 2025 from A$18,644,047 in 2024 ⁶⁸, a 22.7% decrease ⁶⁹, primarily due to the finalization of certain R&D studies ⁷⁰. Conversely, general and administrative expenses increased to A$5,481,399 ⁷¹ from A$4,762,643 in 2024 ⁷², a 15.1% increase ⁷³, mainly due to higher staffing costs, audit compliance, and consulting expenses ⁷⁴. Intellectual property expenses decreased by 40.5% to A$127,523 ⁷⁵ due to management's efforts to reduce expenses and preserve cash ⁷⁶. The company maintains a lean operational structure, with development efforts primarily conducted at research facilities operated by institutions with which it has relationships, minimizing material capital expenditures ⁷⁷. Capital expenditures for the three fiscal years ended June 30, 2025, totaled A$13,033 ⁷⁸. As of June 30, 2025, the company had 9 employees, with seven in research and development and two in management and administration ⁷⁹.

Planned capital allocation includes continued investment in research and development programs, which are expected to require significant additional expenditures for nonclinical testing and clinical trials, as well as regulatory approval ⁸⁰. The company has historically funded operations through equity sales, option exercises, government grants, licensing, and interest income ⁸¹. During the 2025 financial year, the company raised A$4.8 million through a private placement in November 2023 ⁸², A$3.25 million through a placement in February 2024 ⁸³, A$2 million through a Securities Purchase Plan in February 2024 ⁸⁴, and approximately A$40 million through a two-tranche placement in February and April 2025 ⁸⁵. The company does not anticipate paying dividends on its ordinary shares in the foreseeable future, intending to retain future earnings for business use ⁸⁶.

Management explicitly flags that the company will need substantial additional funding to complete the development, testing, and commercialization of its product candidates ⁸⁷. If adequate funding is not available, the company may be required to delay, scale back, or eliminate certain aspects of its operations or obtain funds through unfavorable arrangements that could force it to relinquish rights to technologies or markets, or impose onerous financial terms ⁸⁸. The company's prospects are subject to the inherent risks of a development-stage enterprise, including the uncertainty of research outcomes and commercialization efforts ⁸⁹.

Investing in Alterity's securities involves a high degree of risk and uncertainty, including the inherent risks of a development-stage company engaged in pharmaceutical product development, where success is uncertain ⁹⁰. The company has a history of operating losses and expects to continue incurring substantial and increasing losses while conducting clinical trials ⁹¹. There is a risk that additional funding, which will be needed in the future, may not be available or, if available, could substantially dilute existing shareholders ⁹². Clinical trials are expensive, time-consuming, and their outcome is uncertain, with potential for delays due to government or regulatory issues, slow patient enrollment, manufacturing difficulties, unforeseen safety issues, or lack of efficacy ⁹³. The company relies on research institutions and third-party contractors for clinical trials and manufacturing, which provides less control over timing and cost, and introduces risks of inability to secure or maintain these relationships, or delays in manufacturing sufficient quantities to required standards ⁹⁴. Market acceptance of products is uncertain, even if regulatory approval is obtained, and could be negatively impacted by factors such as demonstrating safety, clinical efficacy, cost-effectiveness, and pricing and reimbursement policies ⁹⁵. Healthcare reform measures and other statutory or regulatory changes, including drug pricing controls and reimbursement limitations, could adversely affect the business ⁹⁶. The company is exposed to product liability claims, which could harm the business, and may not be able to obtain adequate insurance coverage ⁹⁷. Breaches of network or information technology security, natural disasters, or terrorist attacks could have an adverse effect on the business, leading to operational disruptions, data breaches, legal liability, and reputational damage ⁹⁸. The company's success depends on its ability to protect intellectual property, operate without infringing third-party rights, and obtain marketing exclusivity, which is uncertain due to the complex and unpredictable nature of patent matters in the biotechnology industry ⁹⁹. Changes in patent laws or jurisprudence could diminish the value of patents ¹⁰⁰. As an Australian company, it is subject to different corporate requirements and takeover laws that may discourage takeover offers or limit shareholders' strategic opportunities ¹⁰¹. There is a substantial risk that the company is a passive foreign investment company (PFIC) for some U.S. investors, subjecting them to adverse tax rules ¹⁰². Currency fluctuations may adversely affect the price of securities, and failure to maintain compliance with NASDAQ's continued listing requirements could lead to delisting ¹⁰³. Geopolitical instability, such as military conflicts in the Middle East and between Russia and Ukraine, could lead to market disruptions, volatility, and make it more difficult to obtain additional funds ¹⁰⁴.

Management's message to shareholders conveys a tone of cautious optimism, emphasizing the company's commitment to developing first-in-class therapies for neurodegenerative diseases, particularly Parkinsonian and other movement disorders, despite the inherent risks of a development-stage enterprise. They highlight the successful completion of two Phase 2 clinical trials for ATH434 in Multiple System Atrophy (MSA), with topline results from ATH434-201 demonstrating significant slowing of clinical progression and a favorable safety profile, achieving statistical significance on the Modified Unified MSA Rating Scale Part 1 (UMSARS Part 1) ¹⁰⁵. This is presented as an "extremely meaningful" achievement, as UMSARS Part 1 is the endpoint needed to support drug approval by the FDA ¹⁰⁶. Management also points to the positive interim and topline data from the ATH434-202 study in advanced MSA patients, indicating clinical benefit and stabilization of key biomarkers ¹⁰⁷. A key strategic priority is the continued advancement of ATH434 for MSA treatment, supported by its Fast Track and Orphan Drug designations ¹⁰⁸. Another strategic priority is the ongoing development of the company's "platform technology" to create a diversified library of chemical compounds and strengthen its intellectual property portfolio, with the potential to yield future product candidates across various neurodegenerative and other indications ¹⁰⁹. Finally, management emphasizes its ability to successfully raise new equity funding, with A$39,669,380 ¹¹⁰ generated from financing activities in the year ended June 30, 2025, to enable progression of planned research and development programs for at least the next 12 months ¹¹¹, while acknowledging the ongoing need for additional capital to complete development and commercialization ¹¹².